Skip to Content
MilliporeSigma
All Photos(1)

Documents

1478108

USP

Ofloxacin

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H20FN3O4
CAS Number:
82419-36-1
Molecular Weight:
361.37
MDL number:
MFCD00226105
UNSPSC Code:
41116107
PubChem Substance ID:
329750600
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ofloxacin, ofloxacin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)

InChI key

GSDSWSVVBLHKDQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ofloxacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ofloxacin Tablets
  • Ofloxacin Ophthalmic Solution
  • Levofloxacin

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 6

1 of 6

Tinidazole United States Pharmacopeia (USP) Reference Standard

USP

1667520

Tinidazole

Gatifloxacin United States Pharmacopeia (USP) Reference Standard

USP

1288408

Gatifloxacin

Fluconazole United States Pharmacopeia (USP) Reference Standard

USP

1271700

Fluconazole

Steritest® NEO Device For liquids in ampoules or collapsible bags. Blue base canister with a single-needle adapter. Single packed.

Millipore

TZHALA210

Steritest® NEO Device

Levofloxacin Hemihydrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1697

Levofloxacin Hemihydrate

Gentamicin sulfate meets USP testing specifications, powder

Sigma-Aldrich

G1914

Gentamicin sulfate

J P Monk et al.
Drugs, 33(4), 346-391 (1987-04-01)
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other
Mahesh D Chavanpatil et al.
International journal of pharmaceutics, 316(1-2), 86-92 (2006-03-29)
Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window. A new gastroretentive sustained release delivery system was developed
Shu-Hwa Hsiao et al.
The Annals of pharmacotherapy, 39(1), 146-149 (2004-11-25)
To report a case of ofloxacin/levofloxacin-induced rhabdomyolysis and to compare other reported cases from the literature. A 19-year-old male patient developed ofloxacin/levofloxacin-induced rhabdomyolysis during admission for periorbital cellulitis. Symptoms of myalgia, weakness, and swelling of the arms developed after 3
S M Traeger et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 21(6), 1504-1506 (1995-12-01)
We describe four patients who had seizures while receiving ofloxacin; no other causes were evident. Common factors among all patients included advanced age and use of a high-dose regimen. The renal insufficiency of three patients and the timing of the
G A Gates
The Pediatric infectious disease journal, 20(1), 104-107 (2001-02-15)
To assess the safety of topical agents in the middle ear, animal studies were reviewed. Compared with aminoglycoside-containing preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service